UBriGene and Cellinfinity BIO Collaborate to Accelerate in Vivo CAR-T Therapies

Why It Matters

The alliance could reduce CAR‑T production expenses, making these therapies more affordable and expanding patient access. It also advances in‑vivo CAR‑T platforms that address the longstanding challenge of treating solid tumors.

Key Takeaways

• LVV Turbo yields 80% purification recovery.
• Transduction titres increased fivefold with ultra‑T enhancer.
• CIB‑301 targets multiple solid tumor antigens.
• CIB‑350 bispecific CAR addresses B‑cell malignancies.
• Partnership aims to cut CAR‑T production costs.

Pulse Analysis

In‑vivo chimeric antigen receptor T‑cell (CAR‑T) therapy is emerging as a potential solution to the logistical and safety hurdles that have limited the broader adoption of ex‑vivo approaches. By delivering the CAR construct directly into patients, in‑vivo platforms bypass the need for complex cell harvesting, engineering, and cryopreservation steps, which can drive up costs and introduce variability. Analysts estimate the global CAR‑T market will surpass $15 billion by 2030, yet solid‑tumor indications remain under‑represented due to delivery and persistence challenges. The uBriGene‑Cellinfinity collaboration targets precisely these gaps.

uBriGene’s LVV Turbo platform combines a fully closed downstream purification line, the ultra‑T enhancer, and a high‑productivity 293TH suspension cell line. The closed system achieves up to 80 % vector recovery, while the enhancer lifts transduction titres five‑fold, translating into fewer vector batches and lower cost‑of‑goods. Such efficiency is critical for scaling in‑vivo CAR‑T, where viral vector demand can eclipse traditional manufacturing capacities. By offering GMP‑grade lentiviral vectors alongside integrated CDMO and CRO services, uBriGene positions itself as a one‑stop shop for rapid, cost‑effective cell‑therapy development.

Cellinfinity’s CIB‑301 and CIB‑350 candidates stand to benefit from this manufacturing boost. CIB‑301’s fully human scFv is engineered for low off‑target activity across a spectrum of solid‑tumor antigens, while CIB‑350’s bispecific design promises dual‑target engagement in B‑cell malignancies and autoimmune disorders. Faster, cheaper vector production could accelerate clinical timelines, attracting investment and facilitating earlier market entry. If the partnership delivers on its cost‑reduction promise, it may set a new benchmark for the industry, prompting other CDMOs to adopt similar high‑yield platforms and reshaping the economics of next‑generation CAR‑T therapies.